Blogs About Stakeholder Relations
Five Tips for Corporate Social (Media) Responsibility Communications
With sustainability reporting season in high gear, more company leaders are thinking about how social media plays into their overall reporting communications strategy. Whether you’re using social media now or plan to in the future, consider these five tips. Read more →
Where BSR Will Be in June
June is shaping up to be a busy month for BSR staff around the world. Here’s a few of the place we’ll be—and events we’re hosting. We hope to see you there! Read more →
The Future of Nanotechnology for Pharma
Mark Little, Director, Healthcare, Advisory Services
Nanotechnology has supported breakthrough innovation across many industries yet has been met with mixed stakeholder views. Recently, BSR hosted a member event for pharmaceutical companies to discuss nanotechnology applications in the healthcare sector and to consider the related CSR implications. It was an educational experience to be sure with lectures from two science luminaries: Dr. David Hollinshead, Director Science Policy, AstraZeneca and Mike King, an expert from MATTER—a U.K.-based organization focused on stakeholder engagements surrounding new technology applications and their implications for civil society. Compared to the most material issues pharmaceutical companies face—access to medicines, product quality, supply chain, ethics in sales and marketing—nanotechnology is often treated as a horizon issue. While there are some stakeholders with questions around nanotechnology, we learned that the objective science behind nanotechnology stands to bring pharmaceutical companies more opportunities than risks. Nano means “small”—and the simple fact is that smaller particles have larger surface area and are therefore more quickly absorbed into the blood stream. As Dr. David Hollinshead put it, “Nanomedicines are most likely better medicines.” And already, many pharmaceutical companies have begun utilizing nanotechnology to improve drug delivery and targeting. In oncology, for example, nanomedicines are being tested for their ability to reach cell targets that have otherwise eluded more conventional medicines. Yet, the nature of this scientific advancement remains surrounded by “unknown unknowns.” And there is a need for companies—in the pharma sector and beyond—to be proactive in the management and communication of this technology. From MATTER’s “Walking with Stakeholders” project, we know that lack of information is itself a source of distrust among stakeholders. As King put it, “It’s not so much that nano is an issue today, but it’s worth managing and watching closely if only to avoid a situation like that in which Monsanto found itself with GM (genetically modified foods).” So for pharmaceutical companies, the question is not, “Is nano a stakeholder concern?” but rather, “What do we need to learn, and then what do we need to show our stakeholders to gain their trust?” Read more →
Novo Nordisk’s Blueprint for Changing Diabetes in China
Editor’s note: This is the first in a series of blog case studies that look at the sustainability challenges and successes at different pharmaceutical and biotechnology companies. For each case study, we’re interviewing a company practitioner to get an insider’s perspective. We will be publishing these perspectives on a monthly basis and look forward to your comments. If you have a case study that you would like to share, please contact Shivani Kannabhiran at web@bsr.org Read more →
The Economic Power of Women
Amaya Gorostiaga, Former Manager, Advisory Services
Women represent the largest market opportunity in the world. Globally, they control US$20 trillion in annual consumer spending, and this number could rise to US$28 trillion in the next five years. According to the Boston Consulting Group survey “What Women Want,” this potential would constitute a growth market bigger than those of China and India combined. Read more →
More Blogs About Stakeholder Relations
Filter Stakeholder Relations
- 15 Blog Entries
- 47 BSR Insight articles
- No BSR Voices podcasts at this time
- 4 Reports
- 3 Case Studies
- No Sustainable Investment in China articles at this time
- Show All Stakeholder Relations Entries Sorted by Date
